National Learning & Action Network Series: February 2019

Topic: Patient-Centered Treatment Options for Type 2 Diabetes

Date: Wednesday, February 132019

Time: 3:00 - 4:30 PM ET

Registration Required: Register here.


This event is open to beneficiaries, families, healthcare providers, practitioners, partners, End Stage Renal Disease Networks, and Quality Innovation Network-Quality Improvement Organizations.

Event Description:

Selecting the right treatment options for type 2 diabetes has never been more promising, or as complicated as it is today. With all of the current classes of diabetes medications, how does a clinician-patient team decide on the most appropriate medications along the course of a person’s disease process, many of whom also have cardiovascular disease, heart failure, or chronic kidney disease? Join us to learn the latest type 2 diabetes consensus recommendations and decision-trees to help seniors and their care teams decide how to maximize care quality while mitigating risk and treatment burden. This call will feature an author of Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Learning Objectives:

After participating in the event, learner will be able to:

  • Discuss factors affecting treatment selection for type 2 diabetes
  • Use or recommend SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes, atherosclerotic cardiovascular disease, heart failure and chronic kidney disease
  • Appropriately use or recommend GLP-1 receptor agonists as the first injectable for type 2 diabetes treatment, ahead of insulin

Slides & Recorded Presentation:

  • Stay tuned for the slides for this event.
  • Stay tuned for the recorded presentation.

Meet the Speakers:

John Buse, MD, PhD
University of North Carolina School of Medicine

Continuing Education:

Method of Participation:

You must participate in the entire activity to receive credit. A statement of credit will be available upon completion of an online evaluation/​claimed credit form. The link to the online evaluation will be provided after completion of the activity. If you have questions about this CME/CE activity, please contact AKH Inc. at service@​akhcme.​com.

CME/CE Credit Provided by AKH Inc., Advancing Knowledge in Healthcare


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare, CRW & Associates and Telligen. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians. 

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants:

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.


AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 1.5 contact hours (0.15 CEUs). UAN 0077-9999-18-048-L04-P; UAN 0077-9999-18-048-L04-T. Initial Release Date: 11/14/2018


AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is awarded 1.5 contact hours.

Nurse Practitioners:

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare, CRW & Associates and Telligen. 

AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: 030803.

This activity is approved for 1.5 contact hours which includes 0 hour(s) of pharmacology. Activity ID #21868-6.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.


AKH Inc., Advancing Knowledge in Healthcare is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education unit (CPEU) for completion of this program/​material. CDR Accredited Provider #AN008. The focus of this activity is rated Level 2. Learners may submit evaluations of program/​materials quality to the CDR at

Disclosure of Financial Relationships & Commercial Support:

  • AKH Inc., CRW & Associates, and Telligen do not have any relevant financial relationships to disclose.
  • No commercial support was received for this activity.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use and Investigational Product: 

This educational activity may include discussion of uses of agents that are investigational and/​or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/​her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.